ibritumomab tiuxetan (Zevalin®)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Lymphoma, Non-Hodgkin
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Low-Grade
Trial Timeline
Jun 1, 2003 → Oct 31, 2005
NCT ID
NCT00168727About ibritumomab tiuxetan (Zevalin®)
ibritumomab tiuxetan (Zevalin®) is a approved stage product being developed by Biogen for Lymphoma, Non-Hodgkin. The current trial status is completed. This product is registered under clinical trial identifier NCT00168727. Target conditions include Lymphoma, Non-Hodgkin, Lymphoma, Low-Grade.
What happened to similar drugs?
17 of 20 similar drugs in Lymphoma, Non-Hodgkin were approved
Approved (17) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00168727 | Approved | Completed |
Competing Products
20 competing products in Lymphoma, Non-Hodgkin